Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs.

Autor: LeBlanc AK; Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Mazcko CN; Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Fan TM; Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinosis.; Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinosis., Vail DM; Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin., Flesner BK; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri., Bryan JN; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri.; Comparative Oncology Radiobiology and Epigenetics Laboratory, University of Missouri, Columbia, Missouri., Li S; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California., Wang F; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California., Harris S; Cleave Therapeutics Inc., San Francisco, California., Vargas JD; Cleave Therapeutics Inc., San Francisco, California., Govindharajulu JP; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Jaganathan S; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Tomaino F; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Srivastava AK; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Chou TF; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California., Stott GM; NExT Program Support, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Covey JM; Division of Cancer Diagnosis and Treatment and Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Mroczkowski B; Division of Cancer Diagnosis and Treatment and Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Doroshow JH; Division of Cancer Diagnosis and Treatment and Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Oct 07; Vol. 21 (10), pp. 1510-1523.

Sulforaphane is Synergistic with CB-5083 and Inhibits Colony Formation of CB-5083-Resistant HCT116 Cells.

Autor: Wang F; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Li S; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Rosencrans WM; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Cheng KW; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Stott GM; NExT Program Support, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Mroczkowski B; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Chou TF; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.; Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, CA 91125, USA.

Publikováno v: ChemMedChem [ChemMedChem] 2022 Jun 03; Vol. 17 (11), pp. e202200030. Date of Electronic Publication: 2022 Apr 22.

Overcoming Chemoresistance in Cancer: The Promise of Crizotinib.

Autor: Musa, Sanaa^1,2 (AUTHOR), Amara, Noor^1,2 (AUTHOR), Selawi, Adan^1,2 (AUTHOR), Wang, Junbiao³ (AUTHOR), Marchini, Cristina³ (AUTHOR), Agbarya, Abed⁴ (AUTHOR), Mahajna, Jamal^1,2 (AUTHOR) jamalm@migal.org.il

Publikováno v: Cancers. Jul2024, Vol. 16 Issue 13, p2479. 15p.

Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR -, HER2 -, MET - and ROS1 -Alterated Lung Adenocarcinoma.

Autor: Plomer, Eva¹ (AUTHOR) eva.plomer@kssg.ch, Früh, Martin^1,2 (AUTHOR) martin.frueh@kssg.ch, Lauber, Arno³ (AUTHOR) arno.lauber@kssg.ch, Demmer, Izadora⁴ (AUTHOR) izadora.demmerbuchs@kssg.ch, Jochum, Wolfram⁴ (AUTHOR) wolfram.jochum@kssg.ch, Koster, Kira-Lee¹ (AUTHOR) kira-lee.koster@kssg.ch

Publikováno v: International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 11, p5698. 7p.

Transgenic expression of epidermal growth factor and keratinocyte growth factor in β-cells results in substantial morphological changes.

Autor: Krakowski, M. L., Kritzik, M. R., Jones, E. M., Krahl, T., Lee, J., Arnush, M., Gu, D., Mroczkowski, B., Sarvetnick, N.

Publikováno v: Journal of Endocrinology; Aug1999, Vol. 162 Issue 2, p167-175, 9p